125 related articles for article (PubMed ID: 29498921)
21. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.
Mazzaferri EL; Jhiang SM
Am J Med; 1994 Nov; 97(5):418-28. PubMed ID: 7977430
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of recurrence risk in patients with papillary thyroid cancer through tumor-node-metastasis staging: A single-center observational study in Taiwan.
Sun JH; Li YR; Chang KH; Liou MJ; Lin SF; Tsai SS; Yu MC; Hsueh C; Chen ST
Biomed J; 2022 Dec; 45(6):923-930. PubMed ID: 34808423
[TBL] [Abstract][Full Text] [Related]
23. Microscopic positive margins in papillary thyroid cancer do not impact disease recurrence.
Abraham E; Tran B; Roshan D; Graham S; Lehane C; Wykes J; Campbell P; Ebrahimi A
ANZ J Surg; 2018 Nov; 88(11):1193-1197. PubMed ID: 29701284
[TBL] [Abstract][Full Text] [Related]
24. Radioactive iodine treatment for node negative papillary thyroid cancer with capsular invasion only: Results of a large retrospective study.
Jeon YW; Ahn YE; Chung WS; Choi HJ; Suh YJ
Asia Pac J Clin Oncol; 2016 Mar; 12(1):e167-73. PubMed ID: 24289279
[TBL] [Abstract][Full Text] [Related]
25. Investigation of the prognosis of patients with papillary thyroid carcinoma by tumor size.
Ito Y; Fukushima M; Kihara M; Takamura Y; Kobayashi K; Miya A; Miyauchi A
Endocr J; 2012; 59(6):457-64. PubMed ID: 22447137
[TBL] [Abstract][Full Text] [Related]
26. Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.
Chereau N; Dauzier E; Godiris-Petit G; Noullet S; Brocheriou I; Leenhardt L; Buffet C; Menegaux F
Langenbecks Arch Surg; 2018 May; 403(3):325-332. PubMed ID: 29445865
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of tumor multifocality in papillary thyroid carcinoma and its relationship with primary tumor size: a retrospective study of 2,309 consecutive patients.
Kim KJ; Kim SM; Lee YS; Chung WY; Chang HS; Park CS
Ann Surg Oncol; 2015 Jan; 22(1):125-31. PubMed ID: 25092159
[TBL] [Abstract][Full Text] [Related]
28. LncRNA SNHG12 promotes the proliferation and metastasis of papillary thyroid carcinoma cells through regulating wnt/β-catenin signaling pathway.
Ding S; Qu W; Jiao Y; Zhang J; Zhang C; Dang S
Cancer Biomark; 2018; 22(2):217-226. PubMed ID: 29630517
[TBL] [Abstract][Full Text] [Related]
29. Implications of Extrathyroidal Extension Invading Only the Strap Muscles in Papillary Thyroid Carcinomas.
Li G; Li R; Song L; Chen W; Jiang K; Tang H; Wei T; Li Z; Gong R; Lei J; Zhu J
Thyroid; 2020 Jan; 30(1):57-64. PubMed ID: 31830859
[No Abstract] [Full Text] [Related]
30. Number of tumor foci predicts prognosis in papillary thyroid cancer.
Qu N; Zhang L; Ji QH; Zhu YX; Wang ZY; Shen Q; Wang Y; Li DS
BMC Cancer; 2014 Dec; 14():914. PubMed ID: 25471041
[TBL] [Abstract][Full Text] [Related]
31. Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer.
Lee MY; Ku BM; Kim HS; Lee JY; Lim SH; Sun JM; Lee SH; Park K; Oh YL; Hong M; Jeong HS; Son YI; Baek CH; Ahn MJ
Cancer Res Treat; 2017 Oct; 49(4):906-914. PubMed ID: 28052655
[TBL] [Abstract][Full Text] [Related]
32. Papillary thyroid carcinoma with desmoid-type fibromatosis: the clinicopathological features with characteristic imaging and molecular correlation requiring comprehensive treatment.
Huang H; Li L; Liu X; Zhao L; Cui Z; Zhang R; Chen S
Hum Pathol; 2023 Jun; 136():84-95. PubMed ID: 37019411
[TBL] [Abstract][Full Text] [Related]
33. The impact of locoregional recurrences and distant metastases on the survival of patients with papillary thyroid carcinoma.
Su DH; Chang SH; Chang TC
Clin Endocrinol (Oxf); 2015 Feb; 82(2):286-94. PubMed ID: 24863061
[TBL] [Abstract][Full Text] [Related]
34. Assessment of risk factors in metastatic/recurrent tall cell variant of papillary thyroid carcinoma.
Okuyucu K; Alagoz E; Ince S; Arslan N
Endokrynol Pol; 2017; 68(6):623-630. PubMed ID: 29022644
[TBL] [Abstract][Full Text] [Related]
35. MiR-221, a potential prognostic biomarker for recurrence in papillary thyroid cancer.
Dai L; Wang Y; Chen L; Zheng J; Li J; Wu X
World J Surg Oncol; 2017 Jan; 15(1):11. PubMed ID: 28061868
[TBL] [Abstract][Full Text] [Related]
36. Implication of minimal extrathyroidal extension as a prognostic factor in papillary thyroid carcinoma.
Shin JH; Ha TK; Park HK; Ahn MS; Kim KH; Bae KB; Kim TH; Choi CS; Kim TK; Bae SK; Kim SH
Int J Surg; 2013; 11(9):944-7. PubMed ID: 23820062
[TBL] [Abstract][Full Text] [Related]
37. Does microscopically involved margin increase disease recurrence after curative surgery in papillary thyroid carcinoma?
Lang BH; Shek TW; Wan KY
J Surg Oncol; 2016 May; 113(6):635-9. PubMed ID: 26843438
[TBL] [Abstract][Full Text] [Related]
38. Aberrant expression of COT is related to recurrence of papillary thyroid cancer.
Lee J; Jeong S; Park JH; Lee CR; Ku CR; Kang SW; Jeong JJ; Nam KH; Shin DY; Lee EJ; Chung WY; Jo YS
Medicine (Baltimore); 2015 Feb; 94(6):e548. PubMed ID: 25674762
[TBL] [Abstract][Full Text] [Related]
39. USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma.
Jia M; Guo Y; Lu X
Cell Physiol Biochem; 2018; 45(5):2044-2053. PubMed ID: 29533940
[TBL] [Abstract][Full Text] [Related]
40. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
